Phio Pharmaceuticals
| Region | Nordamerika |
| ISIN | US71880W2044 |
| Sektor | Biotechnologie |
| Website | http://www.phiopharma.com |
Phio Pharmaceuticals is focused on developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYLTM) therapeutic platform. Immunotherapies harness our immune system to restore surveillance of tumors that evade detection – a potential curative medicine. INTASYLTM therapeutics can be used as a standalone treatment or in combination with other modalities.
| Titel | Autor | Datum |
|---|---|---|
|
In Wahrheit 100 Mal so viel wert?
|
sharedeals | vor ungefähr 6 Jahren |
| Titel | Datum |
|---|---|
| MISC Secures Shipbuilding Contracts For Two LNG Dual Fuel Suezmax Vessels | vor 4 Tagen |
| MISC adds two LNG dual-fuel Suezmax vessels to its fleet | vor 6 Tagen |
| MISC Unveils Two New LNG Carriers For QatarEnergy Expansion | vor ungefähr einem Monat |
| Stock Picks: MISC And United Plantations | vor ungefähr einem Monat |
| MISC Commits RM40 Million to Develop Malaysia's Maritime Talent | vor ungefähr 2 Monaten |
| Diese Aktien könnten Dich auch interessieren | |
|---|---|
| PayPal (1 Artikel) | |
| Palatin Technologies (4 Artikel) | |
| Premier Gold Mines (1 Artikel) | |
| QIAGEN (1 Artikel) | |
| Alle anzeigen | |